Using CD19 chimeric antigen receptor-T cell therapy in a 4-month-old patient with infantile acute lymphoblastic leukemia

Pediatr Blood Cancer. 2020 Apr;67(4):e28155. doi: 10.1002/pbc.28155. Epub 2020 Jan 11.

Authors

David C Shyr¹, Amy A Homsombath², Priya P Chan¹, Michael W Boyer¹, Andrew C Harris¹

Affiliations

¹ Division of Pediatric Hematology/Oncology, University of Utah School of Medicine, Salt Lake City, Utah.
² Cell Therapy & Regenerative Medicine Program, University of Utah School of Medicine, Salt Lake City, Utah.

PMID: 31925900
DOI: 10.1002/pbc.28155

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antigens, CD19 / immunology*
Female
Humans
Immunotherapy, Adoptive / methods*
Infant
Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology
Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy*
Prognosis

Substances

Antigens, CD19